Oragenics, Inc.
OGEN · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $931 | $450 | $342 | $1,665 |
| G&A Expenses | $2,193 | $1,265 | $1,685 | $1,690 |
| SG&A Expenses | $2,193 | $1,265 | $1,685 | $1,690 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,124 | $1,714 | $2,026 | $3,355 |
| Operating Income | -$3,124 | -$1,714 | -$2,026 | -$3,355 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $57 | -$558 | -$191 | $6 |
| Pre-Tax Income | -$3,067 | -$2,272 | -$2,217 | -$3,349 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,067 | -$2,272 | -$2,217 | -$3,349 |
| % Margin | – | – | – | – |
| EPS | -1.96 | -3.1 | -3.6 | -0.51 |
| % Growth | 36.8% | 13.9% | -605.9% | – |
| EPS Diluted | -1.96 | -3.1 | -3.6 | -0.51 |
| Weighted Avg Shares Out | 16 | 7 | 607 | 6,622 |
| Weighted Avg Shares Out Dil | 16 | 7 | 607 | 6,622 |
| Supplemental Information | – | – | – | – |
| Interest Income | $68 | $17 | $10 | $11 |
| Interest Expense | $7 | $572 | $199 | $11 |
| Depreciation & Amortization | $3,124 | $0 | $0 | $0 |
| EBITDA | $64 | -$1,700 | -$2,018 | -$3,338 |
| % Margin | – | – | – | – |